MedTrace Logo

Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer

NCT02769104 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-01-09

No results posted yet for this study

Summary

The investigators designed this study to investigate the effect of aromatase inhibitors (AI) plus chemotherapy versus chemotherapy as neoadjuvant treatment in postmenopausal hormone receptor-positive breast cancer.

Conditions

  • Neoadjuvant Therapy

Interventions

DRUG

Letrozole (Aromatase Inhibitors)

Letrozole (Aromatase Inhibitors) for 5 years

DRUG

AC*4-T*4

CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Hong-Jian Yang, MD. · Zhejiang Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2018-07-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02769104 on ClinicalTrials.gov